董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steve D. Harr | 男 | Director | 46 | 未披露 | 未持股 | 2017-05-01 |
| Lori A. Kunkel | 女 | Director | 59 | 未披露 | 未持股 | 2017-05-01 |
| Steven A. Elms | 男 | Director | 53 | 18.50万美元 | 未持股 | 2017-05-01 |
| Alan Fuhrman | 男 | Director | 60 | 16.94万美元 | 未持股 | 2017-05-01 |
| David Bonita | 男 | Director | 41 | 16.60万美元 | 未持股 | 2017-05-01 |
| Tim M. Mayleben | 男 | Director | 56 | 16.25万美元 | 未持股 | 2017-05-01 |
| Joshua H. Bilenker | 男 | President and Chief Executive Officer,Director | 45 | 417.57万美元 | 未持股 | 2017-05-01 |
| Keith T. Flaherty | 男 | Director | 46 | 21.75万美元 | 未持股 | 2017-05-01 |
| Avi Z. Naider | 男 | Director | 45 | 16.10万美元 | 未持股 | 2017-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer Burstein | 女 | Vice President of Finance | 45 | 92.21万美元 | 未持股 | 2017-05-01 |
| Jacob Van Naarden | 男 | Chief Business Officer | 32 | 183.59万美元 | 未持股 | 2017-05-01 |
| Joshua H. Bilenker | 男 | President and Chief Executive Officer,Director | 45 | 417.57万美元 | 未持股 | 2017-05-01 |
董事简历
中英对照 | 中文 | 英文- Steve D. Harr
-
SteveD.Harr自2016年11月起担任董事会成员。Harr博士自2014年4月起担任Juno Therapeutics的首席财务官和企业发展主管。此前，他曾在摩根士丹利担任多个职位，包括2010年至2014年担任董事总经理兼全球生物技术投资银行业务主管。在此之前，哈尔博士是摩根士丹利首席生物技术研究分析师和全球梦百合研究联席主管。Harr博士还担任JW Therapeutics的董事会成员。Harr博士在圣十字学院（College of the Holy Cross）获得经济学学士学位，在约翰霍普金斯医学院（Johns Hopkins School of Medicine）获得医学博士学位。
Steve D. Harr has served on the board of directors since November 2016. Dr. Harr has served as Chief Financial Officer and Head of Corporate Development of Juno Therapeutics since April 2014. Previously, he served in various roles at Morgan Stanley, including as Managing Director and Head of Global Biotech Investment Banking from 2010 to 2014. Prior to that, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research. Dr. Harr also serves on the board of directors of JW Therapeutics. Dr. Harr received his B.A. in Economics from the College of the Holy Cross and his M.D. from Johns Hopkins School of Medicine. - SteveD.Harr自2016年11月起担任董事会成员。Harr博士自2014年4月起担任Juno Therapeutics的首席财务官和企业发展主管。此前，他曾在摩根士丹利担任多个职位，包括2010年至2014年担任董事总经理兼全球生物技术投资银行业务主管。在此之前，哈尔博士是摩根士丹利首席生物技术研究分析师和全球梦百合研究联席主管。Harr博士还担任JW Therapeutics的董事会成员。Harr博士在圣十字学院（College of the Holy Cross）获得经济学学士学位，在约翰霍普金斯医学院（Johns Hopkins School of Medicine）获得医学博士学位。
- Steve D. Harr has served on the board of directors since November 2016. Dr. Harr has served as Chief Financial Officer and Head of Corporate Development of Juno Therapeutics since April 2014. Previously, he served in various roles at Morgan Stanley, including as Managing Director and Head of Global Biotech Investment Banking from 2010 to 2014. Prior to that, Dr. Harr was Morgan Stanley’s lead biotech research analyst and co-head of Global Healthcare Research. Dr. Harr also serves on the board of directors of JW Therapeutics. Dr. Harr received his B.A. in Economics from the College of the Holy Cross and his M.D. from Johns Hopkins School of Medicine.
- Lori A. Kunkel
-
LoriA.Kunkel自2019年7月以来一直担任我们的董事会成员。她曾担任LAK505LLC（此前称为D2D，LLC）的生物技术顾问，在那里她曾建议药物开发、战略和商业化（2004年以来）。Kunkel博士从2011年到2013年担任Pharmacyclics LLC的首席医疗官，从2007年到2009年担任Proteolix，Inc.的首席医疗官。从2005年到2007年，Kunkel博士担任Xencor，Inc.临床开发Vice PresidentKunkel博士目前担任Curis，Inc.，Maverick Therapeutics，Inc.和Tocagen，Inc.的董事会成员，并于2014年10月至2019年2月担任LoxoOncology，Inc.的董事。Kunkel博士还担任多家公共和私人生物技术公司的科学顾问。Kunkel博士在加州大学圣地亚哥分校（University of California，San Diego）获得生物学学士学位，在南加州大学（University of Southern California）获得医学博士学位。
Lori A. Kunkel has served as a member of our board of directors since July 2019. Dr. Kunkel is a biotechnology consultant at LAK505 LLC previously D2D, LLC, where she advises on drug development, strategy and commercialization, a position she has held since 2004. Dr. Kunkel served as Chief Medical Officer of Pharmacyclics LLC from 2011 to 2013 and of Proteolix, Inc. from 2007 to 2009. From 2005 to 2007 Dr. Kunkel served as Vice President of Clinical Development of Xencor, Inc. Dr. Kunkel currently serves on the board of directors of Curis, Inc. and Maverick Therapeutics, Inc., and served as a director of Loxo Oncology, Inc. from October 2014 until February 2019 and Tocagen, Inc. from September 2015 until June 2020. Dr. Kunkel also serves as a scientific advisor to a number of public and private biotechnology companies. Dr. Kunkel received a B.A. in Biology from University of California, San Diego and an M.D. from the University of Southern California. - LoriA.Kunkel自2019年7月以来一直担任我们的董事会成员。她曾担任LAK505LLC（此前称为D2D，LLC）的生物技术顾问，在那里她曾建议药物开发、战略和商业化（2004年以来）。Kunkel博士从2011年到2013年担任Pharmacyclics LLC的首席医疗官，从2007年到2009年担任Proteolix，Inc.的首席医疗官。从2005年到2007年，Kunkel博士担任Xencor，Inc.临床开发Vice PresidentKunkel博士目前担任Curis，Inc.，Maverick Therapeutics，Inc.和Tocagen，Inc.的董事会成员，并于2014年10月至2019年2月担任LoxoOncology，Inc.的董事。Kunkel博士还担任多家公共和私人生物技术公司的科学顾问。Kunkel博士在加州大学圣地亚哥分校（University of California，San Diego）获得生物学学士学位，在南加州大学（University of Southern California）获得医学博士学位。
- Lori A. Kunkel has served as a member of our board of directors since July 2019. Dr. Kunkel is a biotechnology consultant at LAK505 LLC previously D2D, LLC, where she advises on drug development, strategy and commercialization, a position she has held since 2004. Dr. Kunkel served as Chief Medical Officer of Pharmacyclics LLC from 2011 to 2013 and of Proteolix, Inc. from 2007 to 2009. From 2005 to 2007 Dr. Kunkel served as Vice President of Clinical Development of Xencor, Inc. Dr. Kunkel currently serves on the board of directors of Curis, Inc. and Maverick Therapeutics, Inc., and served as a director of Loxo Oncology, Inc. from October 2014 until February 2019 and Tocagen, Inc. from September 2015 until June 2020. Dr. Kunkel also serves as a scientific advisor to a number of public and private biotechnology companies. Dr. Kunkel received a B.A. in Biology from University of California, San Diego and an M.D. from the University of Southern California.
- Steven A. Elms
-
Steven A. Elms，自2011任职以来，他担任独立董事和审计委员会的主席和财务专家。他也在提名和薪酬委员会任职。他目前是Aisling Capital（一家领先的投资生命科学公司的私募股权基金）的管理合伙人。此前，他是Hambrecht & Quist的生命科学投资银行部门的高级成员。他从事融资和并购交易60多年并帮助客户筹集超过33亿美元的资本。他获得凯洛格管理研究所的工商管理硕士学位，以及斯坦福大学的人体生物学学士学位。
Steven A. Elms has served as the chairman of board of directors since May 2019 and served as Chief Executive Officer from May 2019 until November 2020. Mr. Elms currently serves as a Managing Partner of Aisling Capital LLC/Aisling Capital Management LP, a life sciences investment firm, which he joined in 2000. Prior to joining Aisling, Mr. Elms served as a principal in the life sciences investment banking group of Chase H&Q formerly Hambrecht and Quist Group Inc.. Mr. Elms has served as a director for Zosano Pharma Corp, a clinical stage biopharmaceutical company, since May 2018 Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, since August 2019 and ADMA Biologics, Inc., a commercial biopharmaceutical company, since July 2007. Previously, Mr. Elms served on the board of directors of Loxo Oncology, Inc. from July 2013 to February 2019 Ambit Biosciences Corp. from 2001 to 2014 MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received a B.A. in Human Biology from Stanford University and a M.B.A. from the Kellogg School of Management at Northwestern University. - Steven A. Elms，自2011任职以来，他担任独立董事和审计委员会的主席和财务专家。他也在提名和薪酬委员会任职。他目前是Aisling Capital（一家领先的投资生命科学公司的私募股权基金）的管理合伙人。此前，他是Hambrecht & Quist的生命科学投资银行部门的高级成员。他从事融资和并购交易60多年并帮助客户筹集超过33亿美元的资本。他获得凯洛格管理研究所的工商管理硕士学位，以及斯坦福大学的人体生物学学士学位。
- Steven A. Elms has served as the chairman of board of directors since May 2019 and served as Chief Executive Officer from May 2019 until November 2020. Mr. Elms currently serves as a Managing Partner of Aisling Capital LLC/Aisling Capital Management LP, a life sciences investment firm, which he joined in 2000. Prior to joining Aisling, Mr. Elms served as a principal in the life sciences investment banking group of Chase H&Q formerly Hambrecht and Quist Group Inc.. Mr. Elms has served as a director for Zosano Pharma Corp, a clinical stage biopharmaceutical company, since May 2018 Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, since August 2019 and ADMA Biologics, Inc., a commercial biopharmaceutical company, since July 2007. Previously, Mr. Elms served on the board of directors of Loxo Oncology, Inc. from July 2013 to February 2019 Ambit Biosciences Corp. from 2001 to 2014 MAP Pharmaceuticals, Inc. from 2004 to 2011 and has served on the boards of directors of a number of private companies. Mr. Elms received a B.A. in Human Biology from Stanford University and a M.B.A. from the Kellogg School of Management at Northwestern University.
- Alan Fuhrman
-
Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University. - Alan Fuhrman目前是Amplyx Pharmaceuticals的首席财务官，这是一家专注于开发针对危及生命的感染的新产品的生物技术公司。在此之前，他于2015年在处于临床阶段的microRNA公司Mirna Therapeutics担任首席财务官，直到2017年8月该公司与Synlogic合并。2010年至2015年，他在环境生物科学公司担任首席财务官，帮助领导公司完成首次公开发行股票，并监督财务、投资者和行政运营，直到2014年将其出售给Daiichi Sankyo。他还曾在私营医疗影像公司Naviscan和上市的专注于肿瘤学的生物技术公司Sonus Pharmaceuticals担任首席财务官。在其职业生涯的早期，Fuhrman先生曾在Coopers & Lybrand担任注册会计师。Fuhrman先生目前在SpringWorks Therapeutics和Checkmate Pharmaceuticals的董事会任职。此前曾于2015年1月至2019年2月在Loxo Oncology董事会任职。Fuhrman先生拥有Montana State大学工商管理和农业经济学学士学位。
- Alan Fuhrman is currently the Chief Financial Officer of Amplyx Pharmaceuticals, a biotechnology company focused on developing novel products for life-threatening infections. Prior to that, he served as Chief Financial Officer of Mirna Therapeutics, a clinical-stage microRNA company, from 2015 until it merged with Synlogic in August 2017. From 2010 to 2015 he served as the Chief Financial Officer at Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He has also served as the CFO at Naviscan, a privately held medical imaging company, and Sonus Pharmaceuticals, a publicly traded oncology-focused biotechnology company. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman currently serves on the Board of Directors of SpringWorks Therapeutics and Checkmate Pharmaceuticals. He previously served on the Board of Directors of Loxo Oncology from January 2015 to February 2019. Mr. Fuhrman holds B.S. degrees in business administration and in agricultural economics from Montana State University.
- David Bonita
-
David Bonita，2004年6月至2013年6月，Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员，自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc，自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.，自2016年3月起担任上市肿瘤学公司Prelude Therapeutics，Inc.自2016年7月起担任上市肿瘤学公司，自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职，此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职，此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位，并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University. - David Bonita，2004年6月至2013年6月，Bonita博士在OrbiMed担任其他职务。Bonita博士自2014年1月起担任上市制药公司Tricida, Inc.的董事会成员，自2016年3月起担任心律失常管理公司Acutus Medical Medical Inc，自2016年3月起担任上市肿瘤学公司Ikena Oncology, Inc.，自2016年3月起担任上市肿瘤学公司Prelude Therapeutics，Inc.自2016年7月起担任上市肿瘤学公司，自2019年9月起担任专注于上市癌症的生物技术公司Repare Therapeutics Inc.的董事会成员。Bonita博士此前还曾于2013年4月至2019年4月在上市制药公司Clementia Pharmaceuticals Inc.的董事会任职，此前曾于2013年10月至2017年12月在上市生物制药公司Loxo Oncology, Inc.、2014年4月至2019年6月在上市医疗器械公司SI-BONE, Inc.以及于2008年1月至2018年6月在上市医疗器械公司ViewRay Inc.任职。Bonita博士目前在多家私营公司的董事会任职，此前也曾任职。Bonita博士此前还曾在摩根士丹利和瑞银的医疗保健投资银行集团担任公司融资分析师。他在哈佛医学院进行的基于信号转导研究的同行评审期刊上发表了科学文章。他在哈佛大学获得生物学学士学位，并在哥伦比亚大学获得联合医学博士/工商管理硕士学位。
- David Bonita,has served as a member of Board since June 2016. Dr. Bonita is a member at OrbiMed Advisors LLC, an investment firm. Dr. Bonita currently serves on the boards of directors of Acutus Medical, Inc., Ikena Oncology, Inc., Repare Therapeutics Inc., and Third Harmonic Bio, Inc., as well as several private companies. Dr. Bonita also previously served on the boards of directors of IMARA Inc. and Tricida, Inc. Prior to OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He received a B.A. in Biology from Harvard University and a joint M.D./M.B.A. from Columbia University.
- Tim M. Mayleben
-
Tim M. Mayleben，自2008年12月以来在本公司的董事会任职。自2012年12月以来，在一家专注于胆固醇升高水平和其它心脏代谢紊乱风险标记治疗疗法的发展和商业化的生物技术公司- Esperion Therapeutic股份有限公司担任总裁、首席执行官和董事。2009年12月-2012年12月期间，他曾是Aastrom Biosciences股份有限公司的总裁、首席执行官和一位董事。2007-2008年期间，曾在NightHawk Radiology控股股份有限公司担任总裁、首席运营官和董事。在加入NightHawk之前，他曾是原来的Esperion股份有限公司的首席运营官和财务总监，一直任到2004年该公司被辉瑞（Pfizer）收购。他还是数个生命科学公司的顾问、投资者和董事会成员，这些公司包括Kaleo股份有限公司、Lycera公司和DeNovo Sciences股份有限公司。Mayleben先生拥有在Northwestern大学J.L. Kellogg管理学研究生院以优异的成绩获得的工商管理学硕士学位，以及拥有Michigan大学Ross商学院的学士学位。
Tim M. Mayleben has served as our President and Chief Executive Officer since December 2012 and as a member of our Board since February 2010. Prior to joining Esperion, Mr. Mayleben was President, CEO and a director of Vericel Corporation NASDAQ: VCEL (formerly Aastrom Biosciences). Previously, Mr. Mayleben was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, he was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma and Marinus Pharmaceuticals (NASDAQ: MRNS). Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business. - Tim M. Mayleben，自2008年12月以来在本公司的董事会任职。自2012年12月以来，在一家专注于胆固醇升高水平和其它心脏代谢紊乱风险标记治疗疗法的发展和商业化的生物技术公司- Esperion Therapeutic股份有限公司担任总裁、首席执行官和董事。2009年12月-2012年12月期间，他曾是Aastrom Biosciences股份有限公司的总裁、首席执行官和一位董事。2007-2008年期间，曾在NightHawk Radiology控股股份有限公司担任总裁、首席运营官和董事。在加入NightHawk之前，他曾是原来的Esperion股份有限公司的首席运营官和财务总监，一直任到2004年该公司被辉瑞（Pfizer）收购。他还是数个生命科学公司的顾问、投资者和董事会成员，这些公司包括Kaleo股份有限公司、Lycera公司和DeNovo Sciences股份有限公司。Mayleben先生拥有在Northwestern大学J.L. Kellogg管理学研究生院以优异的成绩获得的工商管理学硕士学位，以及拥有Michigan大学Ross商学院的学士学位。
- Tim M. Mayleben has served as our President and Chief Executive Officer since December 2012 and as a member of our Board since February 2010. Prior to joining Esperion, Mr. Mayleben was President, CEO and a director of Vericel Corporation NASDAQ: VCEL (formerly Aastrom Biosciences). Previously, Mr. Mayleben was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, he was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Mr. Mayleben is an advisor to, investor in, and member of the board of directors of several life science companies, including Kaléo Pharma and Marinus Pharmaceuticals (NASDAQ: MRNS). Mr. Mayleben earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from the University of Michigan, Ross School of Business.
- Joshua H. Bilenker
-
Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University. - Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
- Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University.
- Keith T. Flaherty
-
Keith T. Flaherty，他是医学博士。他担任我们的董事（2013年9月以来）。他是the Henri and Belinda Termeer Center for Targeted Therapy、Massachusetts General Hospital Cancer Center的董事，也是Harvard Medical School的医学副教授。他曾担任Massachusetts General Hospital的医师（2009年以来）。他目前任职于Clovis Oncology公司（一个生物制药公司）的董事会。他曾接受Brigham and Women''s Hospital内科医学培训、以及宾西法尼亚大学（the University of Pennsylvania）的内科肿瘤学培训，并获得这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及耶鲁大学（Yale University）的神经生物学学士学位。
Keith T. Flaherty has served as a member of the company's board of directors since September 2013. He is Director of the Henri and Belinda Termeer Center for Targeted Therapy and Clinical Research, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School. He has worked as a physician at Massachusetts General Hospital since 2009. Dr. Flaherty serves on the board of directors of Clovis Oncology, Inc., a biopharmaceutical company. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certifications in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree in Neurobiology from Yale University. - Keith T. Flaherty，他是医学博士。他担任我们的董事（2013年9月以来）。他是the Henri and Belinda Termeer Center for Targeted Therapy、Massachusetts General Hospital Cancer Center的董事，也是Harvard Medical School的医学副教授。他曾担任Massachusetts General Hospital的医师（2009年以来）。他目前任职于Clovis Oncology公司（一个生物制药公司）的董事会。他曾接受Brigham and Women''s Hospital内科医学培训、以及宾西法尼亚大学（the University of Pennsylvania）的内科肿瘤学培训，并获得这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及耶鲁大学（Yale University）的神经生物学学士学位。
- Keith T. Flaherty has served as a member of the company's board of directors since September 2013. He is Director of the Henri and Belinda Termeer Center for Targeted Therapy and Clinical Research, Massachusetts General Hospital Cancer Center, and is a Professor of Medicine at Harvard Medical School. He has worked as a physician at Massachusetts General Hospital since 2009. Dr. Flaherty serves on the board of directors of Clovis Oncology, Inc., a biopharmaceutical company. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital, and in medical oncology at the University of Pennsylvania, earning board certifications in these specialties. He received his M.D. from The Johns Hopkins School of Medicine and his B.S. degree in Neurobiology from Yale University.
- Avi Z. Naider
-
Avi Z. Naider，2013年9月以来，他一直担任我们董事会的成员。他是ACES Risk Management公司（一个软件公司）的主席兼首席执行官（2008年1月以来）。加入ACES公司之前，他曾创立MeMedia公司（原名为WhenU.com公司，互联网广告软件公司）。他持有普林斯顿大学（Princeton University）的伍德罗·威尔逊公共和国际事务学院（ the Woodrow Wilson School of Public and International Affairs）的学士学位。
Avi Z. Naider has served as a member of the company's board of directors since September 2013. Mr. Naider is Chairman and CEO of ACES Risk Management Corp., a software company, a position he has held since January 2008. Mr. Naider is also a private investor and consultant to various companies. - Avi Z. Naider，2013年9月以来，他一直担任我们董事会的成员。他是ACES Risk Management公司（一个软件公司）的主席兼首席执行官（2008年1月以来）。加入ACES公司之前，他曾创立MeMedia公司（原名为WhenU.com公司，互联网广告软件公司）。他持有普林斯顿大学（Princeton University）的伍德罗·威尔逊公共和国际事务学院（ the Woodrow Wilson School of Public and International Affairs）的学士学位。
- Avi Z. Naider has served as a member of the company's board of directors since September 2013. Mr. Naider is Chairman and CEO of ACES Risk Management Corp., a software company, a position he has held since January 2008. Mr. Naider is also a private investor and consultant to various companies.
高管简历
中英对照 | 中文 | 英文- Jennifer Burstein
Jennifer Burstein，2015年5月以来，他担任财务副总裁。Loxo Oncology之前从2010年7月到2015年4月，她担任Acorda Therapeutics, Inc.（一个上市的生物科技公司）的财务副总裁。从2006年直到被任命为财务副总裁，她担任不同财务职位并不断被提拔。加入Acorda之前从2002年到2006年，她曾在Eyetech Pharmaceuticals, Inc.（一个公共生物科技公司，目前是Valeant Pharmaceuticals International, Inc.的子公司）的职务。她担任其几个财务职务并不断提拔直到被提拔为会计高级主管。Eyetech之前，她担任几家公司和会计公司的财务部门任职。他获得水牛城the State University of New York的工商管理学士学位并且是纽约注册会计师。
Jennifer Burstein has served as Vice President of Finance since May 2015. Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015 where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006 she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.- Jennifer Burstein，2015年5月以来，他担任财务副总裁。Loxo Oncology之前从2010年7月到2015年4月，她担任Acorda Therapeutics, Inc.（一个上市的生物科技公司）的财务副总裁。从2006年直到被任命为财务副总裁，她担任不同财务职位并不断被提拔。加入Acorda之前从2002年到2006年，她曾在Eyetech Pharmaceuticals, Inc.（一个公共生物科技公司，目前是Valeant Pharmaceuticals International, Inc.的子公司）的职务。她担任其几个财务职务并不断提拔直到被提拔为会计高级主管。Eyetech之前，她担任几家公司和会计公司的财务部门任职。他获得水牛城the State University of New York的工商管理学士学位并且是纽约注册会计师。
- Jennifer Burstein has served as Vice President of Finance since May 2015. Prior to Loxo Oncology, Ms. Burstein served as Vice President of Finance at Acorda Therapeutics, Inc., a public biotechnology company, from July 2010 until April 2015 where she held several positions of increasing responsibility in Finance from 2006 until being appointed Vice President of Finance. Prior to joining Acorda, from 2002 to 2006 she was with Eyetech Pharmaceuticals, Inc., a public biotechnology company, which is currently a subsidiary of Valeant Pharmaceuticals International, Inc., where she held several positions of increasing responsibility in Finance until being promoted to Senior Director, Accounting. Before Eyetech, Ms. Burstein worked in the Finance departments at several companies and in public accounting. Ms. Burstein received her B.S. in Business Administration and M.B.A. in Accounting from the State University of New York at Buffalo and has a CPA license in New York.
- Jacob Van Naarden
Jacob Van Naarden，自2015年12月起担任Loxo Oncology, Inc.首席商务官，自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前，2013年7月至2014年5月，Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月，Mr. Van Naarden曾在Aisling Capital任职，一开始担任分析师后担任助理一职。2006年7月，Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
Jacob Van Naarden,Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development (since 2025). Prior to assuming his expanded role, Mr. Van Naarden served as Executive Vice President and President, Lilly Oncology since 2021. Previously, he served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has seven years of service with Lilly.- Jacob Van Naarden，自2015年12月起担任Loxo Oncology, Inc.首席商务官，自2014年5月担任Loxo Oncology, Inc.开发战略部副总裁。加入Loxo Oncology前，2013年7月至2014年5月，Mr. Van Naarden曾担任HealthCor Management分析师。2008年8月至2013年6月，Mr. Van Naarden曾在Aisling Capital任职，一开始担任分析师后担任助理一职。2006年7月，Mr. Van Naarden在Goldman Sachs开始他的职业生涯直至2008年6月。 Mr. Van Naarden获得了Princeton University分子生物学学士学位。
- Jacob Van Naarden,Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development (since 2025). Prior to assuming his expanded role, Mr. Van Naarden served as Executive Vice President and President, Lilly Oncology since 2021. Previously, he served as chief executive officer-Loxo Oncology at Lilly, and chief operating officer-Loxo Oncology at Lilly. Mr. Van Naarden joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. In previous roles, Mr. Van Naarden worked in various biotechnology investing, operating, and advisory capacities, including positions with HealthCor Management, Aisling Capital, and Goldman Sachs. Mr. Van Naarden has seven years of service with Lilly.
- Joshua H. Bilenker
Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University.- Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
- Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University.